Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Primrose Syndrome

Veronica Arora  1 , Carlos R Ferreira  2 , Ratna Dua Puri  3 , Ishwar Chandar Verma  1
Margaret P Adam, Jerry Feldman, Ghayda M Mirzaa, Roberta A Pagon, Stephanie E Wallace, Anne Amemiya
, editors.
In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
[updated ].
Affiliations
Free Books & Documents
Review

Primrose Syndrome

Veronica Arora et al.
Free Books & Documents

Excerpt

Clinical characteristics: Primrose syndrome is characterized by macrocephaly, hypotonia, developmental delay, intellectual disability with expressive speech delay, behavioral issues, a recognizable facial phenotype, radiographic features, and altered glucose metabolism. Additional features seen in adults: sparse body hair, distal muscle wasting, and contractures. Characteristic craniofacial features include brachycephaly, high anterior hairline, deeply set eyes, ptosis, downslanted palpebral fissures, high palate with torus palatinus, broad jaw, and large ears with small or absent lobes. Radiographic features include calcification of the external ear cartilage, multiple wormian bones, platybasia, bathrocephaly, slender bones with exaggerated metaphyseal flaring, mild epiphyseal dysplasia, and spondylar dysplasia. Additional features include hearing impairment, ocular anomalies, cryptorchidism, and nonspecific findings on brain MRI.

Diagnosis/testing: The diagnosis of Primrose syndrome is established in a proband with characteristic features and a heterozygous pathogenic variant in ZBTB20 identified on molecular genetic testing.

Management: Treatment: Individualized educational program, speech therapy, physical therapy, and occupational therapy as indicated; treatment of behavioral concerns; applied behavioral analysis for autism; standard treatment for seizures, musculoskeletal issues, hearing loss, and thyroid dysfunction; oral hypoglycemics or insulin as needed for diabetes.

Surveillance: Monitor growth and development every six months; speech and developmental assessment every six months; assess for behavioral issues, seizures, and musculoskeletal complications at each visit; brain stem evoked response audiometry annually; annual fasting and postprandial blood glucose, hemoglobin A1c, and assessment for signs and symptoms of thyroid dysfunction.

Genetic counseling: Primrose syndrome is an autosomal dominant disorder. All probands reported to date with Primrose syndrome whose parents have undergone molecular genetic testing have the disorder as a result of a de novo ZBTB20 pathogenic variant. If a parent of the proband is known to have the ZBTB20 pathogenic variant identified in the proband, the risk to the sibs of inheriting the variant is 50%. Once the ZBTB20 pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

PubMed Disclaimer

Similar articles

  • Phelan-McDermid Syndrome-SHANK3 Related.
    Phelan K, Rogers RC, Boccuto L. Phelan K, et al. 2005 May 11 [updated 2024 Jun 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2005 May 11 [updated 2024 Jun 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301377 Free Books & Documents. Review.
  • NFIX-Related Malan Syndrome.
    Priolo M. Priolo M. 2024 Aug 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2024 Aug 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 39083629 Free Books & Documents. Review.
  • Myhre Syndrome.
    Lin AE, Brunetti-Pierri N, Lindsay ME, Schimmenti LA, Starr LJ. Lin AE, et al. 2017 Apr 13 [updated 2024 Dec 12]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2017 Apr 13 [updated 2024 Dec 12]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 28406602 Free Books & Documents. Review.
  • FAM111A-Related Skeletal Dysplasias.
    Cheng S, Lo IFM, Luk HM. Cheng S, et al. 2023 Apr 6. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2023 Apr 6. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 37023242 Free Books & Documents. Review.
  • TET3-Related Beck-Fahrner Syndrome.
    Fahrner JA. Fahrner JA. 2023 May 18. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2023 May 18. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 37200470 Free Books & Documents. Review.
See all similar articles

References

    1. Arora V, Leon E, Diaz J, Hove HB, Carvalho DR, Kurosawa K, Nishimura N, Nishimura G, Saxena R, Ferreira C, Puri RD, Verma IC. Unique skeletal manifestations in patients with Primrose syndrome. Eur J Med Genet. 2020;63:103967. - PMC - PubMed
    1. Battisti C, Dotti MT, Cerase A, Rufa A, Sicurelli F, Scarpini C, Federico A. The Primrose syndrome with progressive neurological involvement and cerebral calcification. J Neurol. 2002;249:1466–8. - PubMed
    1. Carvalho DR, Speck-Martins CE. Additional features of unique Primrose syndrome phenotype. Am J Med Genet. 2011;155A:1379–83. - PubMed
    1. Cleaver R, Berg J, Craft E, Foster A, Gibbons RJ, Hobson E, Lachlan K, Naik S, Sampson JR, Sharif S, Smithson S, Parker MJ, Tatton-Brown K, et al. Refining the Primrose syndrome phenotype: a study of five patients with ZBTB20 de novo variants and a review of the literature. Am J Med Genet A. 2019;179:344–9. - PubMed
    1. Dalal P, Leslie ND, Lindor NM, Giulbert DL, Espay AJ. Motor tics, stereotypies, and self-flagellation in Primrose syndrome. Neurology. 2010;75:284–6. - PMC - PubMed

LinkOut - more resources